Ventyx Biosciences Surges 90% as Company Reports Data Win in CV, Market Cap Valuation Tops $500M

Ventyx Biosciences shares are up 90% after a data win in cardiovascular disease. The company's stock has reached a value of over $7 per share and a market cap valuation of over $500m. The investment overview notes the significant increase in the share price, reaching a value of over $7 per share and a market cap valuation of over $500m. The article provides an overview of the company's investment, including the recent data win in cardiovascular disease, which has contributed to the significant increase in the share price.